297. アラジール症候群 Alagille syndrome Clinical trials / Disease details
臨床試験数 : 45 / 薬物数 : 21 - (DrugBank : 10) / 標的遺伝子数 : 3 - 標的パスウェイ数 : 5
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05543174 (ClinicalTrials.gov) | January 16, 2023 | 14/9/2022 | A Study of TAK-625 for the Treatment of Alagille Syndrome (ALGS) | An Open-Label, Phase 3 Study to Evaluate the Efficacy and Safety of TAK-625 in the Treatment of Subjects With Alagille Syndrome | Alagille Syndrome (ALGS) | Drug: TAK-625 | Takeda | NULL | Recruiting | 1 Month | N/A | All | 5 | Phase 3 | Japan |